Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CXCR2 | P25025 | 4/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | TSHR | P16473 | 5/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 5/20 | 0.40 |
| ▸ | LMNA | P02545 | 5/20 | 0.40 |
| ▸ | MEN1 | O00255 | 4/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.40 |
| ▸ | HPGD | P15428 | 4/20 | 0.40 |
| ▸ | HTT | P42858 | 4/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.40 |
| ▸ | XBP1 | P17861 | 3/20 | 0.40 |
| ▸ | TP53 | P04637 | 3/20 | 0.40 |
| ▸ | PKM | P14618 | 3/20 | 0.40 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | JAK2 | O60674 | 2/20 | 0.39 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.39 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | CTSS | P25774 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3375480 | 0.85 | CXCR2 (0.42) | CXCR2ALDH1A1TSHRNPSR1LMNA | |
| SCHEMBL18878153 | 0.77 | ALDH1A1 (0.43) | ALDH1A1TSHRNPSR1LMNAMEN1 | |
| SCHEMBL14327806 | 0.75 | CTSK (0.47) | ALDH1A1HPGDCTSSCTSKMAPT | |
| SCHEMBL5212724 | 0.75 | CTSK (0.56) | ALDH1A1TSHRLMNAHPGDHSD17B10 | |
| SCHEMBL9608914 | 0.75 | CTSK (0.56) | ALDH1A1TSHRLMNAHPGDHSD17B10 | |
| SCHEMBL12203909 | 0.75 | CTSK (0.56) | ALDH1A1TSHRLMNAHPGDHSD17B10 | |
| SCHEMBL22457063 | 0.74 | JAK2 (0.43) | ALDH1A1TSHRNPSR1LMNAMEN1 | |
| SCHEMBL15241731 | 0.72 | FAAH (0.57) | ALDH1A1TSHRLMNAMEN1KMT2A | |
| SCHEMBL15092632 | 0.72 | MAPT (0.48) | ALDH1A1LMNAXBP1PKMSMN1; SMN2 | |
| SCHEMBL31017568 | 0.72 | MAPT (0.48) | ALDH1A1LMNAXBP1PKMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9115087-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20140213594-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-07-31 | — | — | US | disclosed |
| US-8722925-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2014-05-13 | — | — | US | disclosed |
| EP-2310359-B1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2014-01-15 | — | — | EP | disclosed |
| US-20130005735-A1 | ORGANIC COMPOUNDS | NOVARTIS AG | 2013-01-03 | — | — | US | disclosed |
| US-8329754-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2012-12-11 | — | — | US | disclosed |
| US-8288588-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2012-10-16 | — | — | US | disclosed |
| US-8183281-B2 | CXC-chemokine receptor ligands | NOVARTIS AG (CH) | 2012-05-22 | — | — | US | disclosed |
| EP-2155670-B1 | ANTI -INFLAMMATORY SUBSTITUTED CYCLOBUTENEDIONE COMPOUNDS | NOVARTIS AG (CH) | 2012-04-18 | — | — | EP | disclosed |
| US-20110251206-A1 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | NOVARTIS AG | 2011-10-13 | — | — | US | disclosed |
| US-7989497-B2 | Squaramide derivatives as CXCR2 antagonist | NOVARTIS AG (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | NOVARTIS AG (CH) | 2010-05-20 | — | — | US | disclosed |
| US-20100029670-A1 | ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2010-02-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100125071-A1 | CXC-CHEMOKINE RECEPTOR LIGANDS | CXCR2, CXCR1, CX3CR1 | CXCR2 1/4885ALDH1A1 792/4885TSHR 1085/4885 |
| US-20110251206-A1 | Squaramide derivatives as CXCR2 antagonist | CXCR2, CXCR3, CXCR1 | CXCR2 1/4885ALDH1A1 3014/4885TSHR 671/4885 |
| US-20110251205-A1 | SQUARAMIDE DERIVATIVES AS CXCR2 ANTAGONIST | CXCR2, CXCR3, CXCR1 | CXCR2 1/4885ALDH1A1 3014/4885TSHR 671/4885 |
| US-20100029670-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885ALDH1A1 607/4885TSHR 824/4885 |
| US-20130005735-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885ALDH1A1 607/4885TSHR 824/4885 |
| US-20140213594-A1 | ORGANIC COMPOUNDS | CXCR2, CXCR1, CXCR3 | CXCR2 1/4885ALDH1A1 607/4885TSHR 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.